Home Zacks Investment Research Downgrades Celsion Co. (CLSN) to Sell
 

Keywords :   


Zacks Investment Research Downgrades Celsion Co. (CLSN) to Sell

2016-04-05 02:28:40| Biotech - Topix.net

According to Zacks, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.

Tags: research sell investment downgrades

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11 24.525.5cm
25.11 B
25.11SHIMANO CS-R8000 14-28t 1
25.11RADWIMPS/
25.11Delegation Delegation
25.11009 19685DVD
25.1124 C2000S
25.11stayc applemusic so bad 1
More »